First Patient Enrolled and Dosed in Novan's SB206 Phase 3 Molluscum Program

Stock Information for Novan Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Novan Inc.

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
Novan Focuses Strategic Direction and Announces Restructuring
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
Novan to Host Analyst and Investor Event: A Discussion of Molluscum's Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.